bioRxivImmunologyPreprint
Targeting conserved viral virulence determinants by single domain antibodies to block SARS-CoV2 infectivity
S. Singh, S. Dahiya, Y. J. Singh, K. Beeton, A. Jain, R. Sarkar, A. Dubey, S. A. Tehseen, S. Sehrawat
Abstract
We selected SARS-CoV2 specific single domain antibodies (sdAbs) from a previously constructed phage display library using synthetic immunogenic peptides of the virus spike (S) protein as bait. The sdAbs targeting the cleavage site (CS) and the receptor binding domain (RBD) in S protein efficiently neutralised the infectivity of a pseudovirus expressing SARS-CoV2 S protein. Anti-CS sdAb blocked the virus infectivity by inhibiting proteolytic processing of SARS-CoV2 S protein. Both the sdAbs retained characteristic structure within the pH range of 2 to 12 and remained stable upto 65{degrees}C. Furthermore, structural disruptions induced by a high temperature in both the sdAbs were largely reversed upon their gradual cooling and the resulting products neutralised the reporter virus. Our results therefore suggest that targeting CS in addition to the RBD of S protein by sdAbs could serve as a viable option to reduce SARS-CoV2 infectivity and that proteolytic processing of the viral S protein is critical for infection.
- organism: virus
- assay: proteomics
- research focus: drug response / drug discovery
- approach: experimental assay
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Humanized Single Domain Antibodies Neutralize SARS-CoV-2 by Targeting Spike Receptor Binding Domain
- A potent neutralizing human antibody reveals the N-terminal domain of the Spike protein of SARS-CoV-2 as a site of vulnerability
- SARS-CoV-2 receptor binding domain fusion protein efficiently neutralizes virus infection
A. E. Chaouat, H. Achdout, … O. Mandelboim·bioRxiv·Apr 18, 2021
- Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability
P. Brouwer, T. Caniels, … M. van Gils·bioRxiv·May 12, 2020
- The Development of a Novel Nanobody Therapeutic for SARS-CoV-2
G. Ye, J. Gallant, … F. Li·bioRxiv·Nov 17, 2020
- Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein
S. J. Zost, P. Gilchuk, … J. E. Crowe·bioRxiv·May 12, 2020